Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations

Frontiers in Oncology

Volumn 4 FEB, Issue , 2014, Pages

  Goltsov, Alexey ^a   Langdon, Simon P ^b   Goltsov, Gregory ^c   Harrison, David J ^d   Bown, James ^a  

^a UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Touch Surgery   (United Kingdom)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Anti cancer combination therapy; Cancer drug resistance; Pathway engineering; Pertuzumab; PI3K PTEN AKT; Signaling networks

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; RAS PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84898015235     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00013     Document Type: Article

References (72)

1. Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol (2013) 31:1592-605. doi: 10.1200/JCO.2011.37.6418
2. Jørgensen JT. Companion diagnostics in oncology - current status and future aspects. Oncology (2013) 85:59-68. doi:10.1159/000353454
3. US Food and Drug Administration. New Guidance for Industry: Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm237264.htm
4. Chandarlapaty S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov (2012) 2:311-9. doi:10.1158/2159-8290.CD-12-0018
5. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene (2008) 27:5527-41. doi:10.1038/onc.2008.247
6. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther (2010) 9:3137-44. doi:10.1158/1535-7163.MCT-10-0642
7. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel (2010) 13:297-309.
8. Nelander S, Wang W, Nilsson B, She Q-B, Pratilas C, Rosen N, et al. Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol (2008) 4:216. doi:10.1038/msb.2008.53
9. Tang J, Karhinen L, Xu T, Szwajda A, Yadav B, Wennerberg K, et al. Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. Roth FP, editor. PLoS Comput Biol (2013) 9:e1003226. doi:10.1371/journal.pcbi.1003226
10. Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2012) 366:109-19. doi:10.1056/NEJMoa1113216
11. Faratian D, Zweemer AJM, Nagumo Y, Sims AH, Muir M, Dodds M, et al. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res (2011) 17:4451-61. doi:10.1158/1078-0432.CCR-10-2461
12. Sims AH, Zweemer AJM, Nagumo Y, Faratian D, Muir M, Dodds M, et al. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br J Cancer (2012) 106:1779-89. doi:10.1038/bjc.2012.176
13. Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res (2012) 72:210-9. doi:10.1158/0008-5472.CAN-11-1515
14. Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer (2012) 106:1386-94. doi:10.1038/bjc.2012.70
15. Sharial M, Crown J, Hennessy BT. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol (2012) 23:3007-16. doi:10.1093/annonc/mds200
16. Zheng J, Hudder A, Zukowski K, Novak RF. Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer Lett (2010) 296:74-87. doi:10.1016/j.canlet.2010.03.018
17. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 29:3126-32. doi:10.1200/JCO.2010.32.2321
18. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 12:487-93. doi:10.1038/nrc3298
19. Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, et al. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis (2013) 34:725-38. doi:10.1093/carcin/bgt086
20. Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol (2013) 3:259. doi:10.3389/fonc.2013.00259
21. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 27:1999-2006. doi:10.1200/JCO.2008.19.6618
22. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell (2012) 149:780-94. doi:10.1016/j.cell.2012.03.031
23. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther (2011) 10:2426-36. doi:10.1158/1535-7163.MCT-11-0446
24. Nahta R, O'Regan RM. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer (2010) 10(Suppl 3):S72-8. doi:10.3816/CBC.2010.s.015
25. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 15:429-40. doi:10.1016/j.ccr.2009.03.020
26. Sturm OE, Orton R, Grindlay J, Birtwistle M, Vyshemirsky V, Gilbert D, et al. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci Signal (2010) 3:ra90. doi:10.1126/scisignal.2001212
27. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 367:1694-703. doi:10.1056/NEJMoa1210093
28. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 366:883-92. doi:10.1056/NEJMoa1113205
29. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 72:2176-82. doi:10.1158/0008-5472.CAN-11-3980
30. Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res (2009) 69:6713-20. doi:10.1158/0008-5472.CAN-09-0777
31. Goltsov A, Deeni Y, Khalil H, Idowu M, Kyriakidis S, Goltsov G, et al. Role of post-translational regulation of PTEN activity in cancer cell addiction to heterozygous PTEN mutations. In: Xu K, editor. PTEN Structure, Mechanism of Action, Role Cell Signalling and Regulation. Hauppauge, NY: Nova Science Publishers (2013). p. 173-210.
32. Goltsov A, Faratian D, Langdon SP, Bown J, Goryanin I, Harrison DJ. Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition. Cell Signal (2011) 23:407-16. doi:10.1016/j.cellsig.2010.10.011
33. Hua F, Cornejo MG, Cardone MH, Stokes CL, Lauffenburger DA. Effects of Bcl-2 levels on Fas signaling-induced caspase-3 activation: molecular genetic tests of computational model predictions. J Immunol (2005) 175:985-95.
34. Wolf J, Dronov S, Tobin F, Goryanin I. The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations. FEBS J (2007) 274:5505-17. doi:10.1111/j.1742-4658.2007.06066.x
35. Orton RJ, Adriaens ME, Gormand A, Sturm OE, Kolch W, Gilbert DR. Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway. BMC Syst Biol (2009) 3:100. doi:10.1186/1752-0509-3-100
36. Yoon J, Deisboeck TS. Investigating differential dynamics of the MAPK signaling cascade using a multi-parametric global sensitivity analysis. PLoS One (2009) 4:e4560. doi:10.1371/journal.pone.0004560
37. Dana S, Nakakuki T, Hatakeyama M, Kimura S, Raha S. Computation of restoration of ligand response in the random kinetics of a prostate cancer cell signaling pathway. Comput Methods Programs Biomed (2011) 101:1-22. doi:10.1016/j.cmpb.2010.04.001
38. Nguyen LK, Matallanas D, Croucher DR, von Kriegsheim A, Kholodenko BN. Signalling by protein phosphatases and drug development: a systems-centred view. FEBS J (2013) 280:751-65. doi:10.1111/j.1742-4658.2012.08522.x
39. Zou X, Liu M, Pan Z. Robustness analysis of EGFR signaling network with a multi-objective evolutionary algorithm. Biosystems (2008) 91:245-61. doi:10.1016/j.biosystems.2007.10.001
40. Goltsov A, Faratian D, Langdon SP, Mullen P, Harrison DJ, Bown J. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. Cell Signal (2012) 24:493-504. doi:10.1016/j.cellsig.2011.09.030
41. Lebedeva G, Sorokin A, Faratian D, Mullen P, Goltsov A, Langdon SP, et al. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network. Eur J Pharm Sci (2012) 46:244-58. doi:10.1016/j.ejps.2011.10.026
42. Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 15:4147-56. doi:10.1158/1078-0432.CCR-08-2814
43. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo W-L, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 68:6084-91. doi:10.1158/0008-5472.CAN-07-6854
44. Cheung LWT, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 1:170-85. doi:10.1158/2159-8290.CD-11-0039
45. Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol Cancer Res (2009) 7:1563-71. doi:10.1158/1541-7786.MCR-09-0101
46. Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, et al. Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer. Cell Signal (2013) 25:26-32. doi:10.1016/j.cellsig.2012.09.014
47. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 5:317-28. doi:10.1016/S1535-6108(04)00083-2
48. Leslie NR, Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci (2011) 32:131-40. doi:10.1016/j.tips.2010.12.005
49. Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, Lauffenburger DA, et al. Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol (2009) 5:239. doi:10.1038/msb.2008.74
50. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal (2009) 2:ra31. doi:10.1126/scisignal.2000352
51. Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, List H-J, et al. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene (2003) 22:2073-87. doi:10.1038/sj.onc.1206769
52. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol (2006) 2:458-66. doi:10.1038/nchembio817
53. Kessler T, Hache H, Wierling C. Integrative analysis of cancer-related signaling pathways. Front Physiol (2013) 4:124. doi:10.3389/fphys.2013.00124
54. Nagashima T, Shimodaira H, Ide K, Nakakuki T, Tani Y, Takahashi K, et al. Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation. J Biol Chem (2007) 282:4045-56. doi:10.1074/jbc.M608653200
55. Park CS, Schneider IC, Haugh JM. Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signaling in fibroblasts. J Biol Chem (2003) 278:37064-72. doi:10.1074/jbc.M304968200
56. Goldbeter A, Koshland DE. An amplified sensitivity arising from covalent modification in biological systems. Proc Natl Acad Sci U S A (1981) 78:6840-4. doi:10.1073/pnas.78.11.6840
57. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res (2008) 10:R101. doi:10.1186/bcr2204
58. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 65:2554-9. doi:10.1158/0008-5472-CAN-04-3913
59. Byun D-S, Cho K, Ryu B-K, Lee M-G, Park J-I, Chae K-S, et al. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer (2003) 104:318-27. doi:10.1002/ijc.10962
60. Berns K, Bernards R. Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist Updat (2012) 15:268-75. doi:10.1016/j.drup.2012.10.002
61. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer (2004) 4:227-35. doi:10.1038/nrc1300
62. Stelling J, Sauer U, Szallasi Z, Doyle FJ, Doyle J. Robustness of cellular functions. Cell (2004) 118:675-85. doi:10.1016/j.cell.2004.09.008
63. Lee AJX, Swanton C. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics. Biochem Pharmacol (2012) 83:1013-20. doi:10.1016/j.bcp.2011.12.008
64. Hengel SM, Murray E, Langdon S, Hayward L, O'Donoghue J, Panchaud A, et al. Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. J Proteome Res (2011) 10:4567-78. doi:10.1021/pr2004117
65. Cooke SL, Ng CKY, Melnyk N, Garcia MJ, Hardcastle T, Temple J, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene (2010) 29:4905-13. doi:10.1038/onc.2010.245
66. Simon R. Drug-diagnostics co-development in oncology. Front Oncol (2013) 3:315. doi:10.3389/fonc.2013.00315
67. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A (2012) 109:2718-23. doi:10.1073/pnas.1018001108
68. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res (2009) 69:2191-4. doi:10.1158/0008-5472.CAN-08-1056
69. Pryciak PM. Systems biology. Customized signaling circuits. Science (2008) 319:1489-90. doi:10.1126/science.1156414
70. Brandman O, Meyer T. Feedback loops shape cellular signals in space and time. Science (2008) 322:390-5. doi:10.1126/science.1160617
71. Bashor CJ, Helman NC, Yan S, Lim WA. Using engineered scaffold interactions to reshape MAP kinase pathway signaling dynamics. Science (2008) 319:1539-43. doi:10.1126/science.1151153
72. Behar M, Barken D, Werner SL, Hoffmann A. The dynamics of signaling as a pharmacological target. Cell (2013) 155:448-61. doi:10.1016/j.cell.2013.09.018